File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Blockade of glioma proliferation through allosteric inhibition of JAK2

TitleBlockade of glioma proliferation through allosteric inhibition of JAK2
Authors
Issue Date2013
Citation
Science Signaling, 2013, v. 6, n. 283 How to Cite?
AbstractThe gene that encodes the epidermal growth factor receptor (EGFR) is frequently overexpressed or mutated in human cancers, including glioblastoma. However, the efficacy of EGFR-targeted small-molecule inhibitors or monoclonal antibodies in glioblastomas that also have mutation or deletion of the gene encoding phosphatase and tensin homolog (PTEN) has been modest. We found that EGFR signaling was blocked by a small molecule (G5-7) that selectively inhibited Janus kinase 2 (JAK2)-mediated phospho-rylation and activation of EGFR and STAT3 (signal transducer and activator of transcription 3) by binding to JAK2, thereby decreasing the activity of downstream signaling by mTOR (mammalian target of rapamycin) and inducing cell cycle arrest. G5-7 inhibited the proliferation of PTEN-deficient glioblastoma cell lines harboring a constitutively active variant of EGFR (U87MG/EGFRvIII) and human glioblastoma explant neu-rosphere cultures, but the drug only weakly inhibited the proliferation of either glioblastoma cell lines that were wild type for EGFR and stably transfected with PTEN (U87MG/PTEN) or normal neural progenitor cells and astrocytes. Additionally, G5-7 reduced vascular endothelial growth factor (VEGF) secretion and endothelial cell migration and induced apoptosis in glioblastoma xenografts, thereby suppressing glioblastoma growth in vivo. Furthermore, G5-7 was more potent than EGFR or JAK2 inhibitors that interfere with either ligand or adenosine 5′-triphosphate (ATP) binding at impeding glioblastoma cell proliferation, demonstrating that this allosteric JAK2 inhibitor may be an effective clinical strategy. Copyright 2008 American Association for the Advancement of Science. All Rights Reserved.
Persistent Identifierhttp://hdl.handle.net/10722/225055
ISSN
2015 Impact Factor: 7.359

 

DC FieldValueLanguage
dc.contributor.authorHe, Kunyan-
dc.contributor.authorQi, Qi-
dc.contributor.authorChan, Chi Bun-
dc.contributor.authorXiao, Ge-
dc.contributor.authorLiu, Xia-
dc.contributor.authorTucker-Burden, Carol-
dc.contributor.authorWang, Liya-
dc.contributor.authorMao, Hui-
dc.contributor.authorLu, Xiang-
dc.contributor.authorMcDonald, Frank E.-
dc.contributor.authorLuo, Hongbo-
dc.contributor.authorFan, Qi Wen-
dc.contributor.authorWeiss, William A.-
dc.contributor.authorSun, Shi Yong-
dc.contributor.authorBrat, Daniel J.-
dc.contributor.authorYe, Keqiang-
dc.date.accessioned2016-04-18T11:16:38Z-
dc.date.available2016-04-18T11:16:38Z-
dc.date.issued2013-
dc.identifier.citationScience Signaling, 2013, v. 6, n. 283-
dc.identifier.issn1945-0877-
dc.identifier.urihttp://hdl.handle.net/10722/225055-
dc.description.abstractThe gene that encodes the epidermal growth factor receptor (EGFR) is frequently overexpressed or mutated in human cancers, including glioblastoma. However, the efficacy of EGFR-targeted small-molecule inhibitors or monoclonal antibodies in glioblastomas that also have mutation or deletion of the gene encoding phosphatase and tensin homolog (PTEN) has been modest. We found that EGFR signaling was blocked by a small molecule (G5-7) that selectively inhibited Janus kinase 2 (JAK2)-mediated phospho-rylation and activation of EGFR and STAT3 (signal transducer and activator of transcription 3) by binding to JAK2, thereby decreasing the activity of downstream signaling by mTOR (mammalian target of rapamycin) and inducing cell cycle arrest. G5-7 inhibited the proliferation of PTEN-deficient glioblastoma cell lines harboring a constitutively active variant of EGFR (U87MG/EGFRvIII) and human glioblastoma explant neu-rosphere cultures, but the drug only weakly inhibited the proliferation of either glioblastoma cell lines that were wild type for EGFR and stably transfected with PTEN (U87MG/PTEN) or normal neural progenitor cells and astrocytes. Additionally, G5-7 reduced vascular endothelial growth factor (VEGF) secretion and endothelial cell migration and induced apoptosis in glioblastoma xenografts, thereby suppressing glioblastoma growth in vivo. Furthermore, G5-7 was more potent than EGFR or JAK2 inhibitors that interfere with either ligand or adenosine 5′-triphosphate (ATP) binding at impeding glioblastoma cell proliferation, demonstrating that this allosteric JAK2 inhibitor may be an effective clinical strategy. Copyright 2008 American Association for the Advancement of Science. All Rights Reserved.-
dc.languageeng-
dc.relation.ispartofScience Signaling-
dc.titleBlockade of glioma proliferation through allosteric inhibition of JAK2-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1126/scisignal.2003900-
dc.identifier.pmid23838182-
dc.identifier.scopuseid_2-s2.0-84880899903-
dc.identifier.volume6-
dc.identifier.issue283-
dc.identifier.eissn1937-9145-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats